Business Context and Reporting Period
This Form 8-K reports on events occurring on June 17, 2026, specifically the 2026 Annual Meeting of Stockholders for Acrivon Therapeutics, Inc. (ACRV). The filing details the election of directors, the ratification of the independent auditor, and the approval of an amended equity incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Equity Plan Approval: Stockholders approved the Amended and Restated 2022 Equity Incentive Plan. The total share reserve is now 8,606,723 shares, reflecting an increase of 3,000,000 shares.
- Automatic Increase Mechanism: The plan includes a provision for the share reserve to automatically increase on January 1 of each year through 2032 by 5% of the Company's fully diluted shares outstanding on the preceding December 31.
- Director Elections: Michael Tomsicek, M.B.A., and Charles Baum, M.D., Ph.D., were elected as Class I Directors to serve until the 2029 Annual Meeting.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Voting Results and Management Commentary
A quorum of 31,336,993.43 shares (73.21% of outstanding shares) was present at the meeting. The voting results were as follows:
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Michael Tomsicek | 24,020,408 | 1,229,385 | N/A | 6,087,200 |
| Election of Charles Baum | 23,657,074 | 1,592,719 | N/A | 6,087,200 |
| Ratification of Auditor (PwC) | 31,278,962 | 53,857 | 4,174 | 0 |
| Approval of Equity Incentive Plan | 20,546,400 | 3,757,400 | 104,757 | 6,928,436 |
Management commentary is limited to the stated purposes of the equity plan: to secure and retain employees, directors, and consultants, and to provide incentives tied to the value of the Company's common stock.
Investor Verification Checklist
- Verify the full text of the Amended and Restated 2022 Equity Incentive Plan (Exhibit 10.1) to understand specific vesting schedules and performance metrics.
- Monitor the automatic share reserve increase mechanism effective January 1, 2027, which could impact future dilution.
- Review the 2026 Annual Report (Form 10-K) for the financial performance data not included in this 8-K filing.
- Confirm the tenure and background of the newly elected directors, Michael Tomsicek and Charles Baum.